Johnson & Johnson (NYSE:JNJ) Shares Acquired by Bell Rock Capital LLC

Bell Rock Capital LLC increased its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 469.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,346 shares of the company’s stock after acquiring an additional 6,881 shares during the quarter. Johnson & Johnson makes up about 1.7% of Bell Rock Capital LLC’s portfolio, making the stock its 15th biggest holding. Bell Rock Capital LLC’s holdings in Johnson & Johnson were worth $1,363,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Morton Brown Family Wealth LLC lifted its holdings in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $39,000. Cardinal Capital Management Inc. boosted its position in Johnson & Johnson by 333.3% during the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares during the last quarter. First Bank & Trust grew its stake in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $84,000. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Atlantic Securities dropped their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James cut their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, October 19th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Bank of America reduced their target price on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Finally, Sanford C. Bernstein dropped their price target on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $182.42.

Johnson & Johnson Stock Down 0.3 %

Johnson & Johnson stock opened at $173.43 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm has a 50 day moving average price of $176.33 and a 200 day moving average price of $171.44. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a market capitalization of $453.43 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.60 EPS. Research analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is 62.95%.

Insider Buying and Selling

In other Johnson & Johnson news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at $18,864,202. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the completion of the transaction, the vice president now directly owns 114,676 shares of the company’s stock, valued at $18,864,202. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Robert J. Decker sold 16,928 shares of the firm’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The disclosure for this sale can be found here. Insiders have sold a total of 300,750 shares of company stock valued at $52,311,677 in the last ninety days. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.